SLC1A5 and breast cancer: Indeed, while cell fusion can be also detected in breast cancers and others [22,23], endothelial ASCT2 (alanine, serine, and cysteine selective transporter-2) can function as a syncytin receptor to mediate the heterofusion of breast cancer cells with endothelial cells [24,25].